CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 6.32: safe zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.76%
Annual Rate
CNY 0.60Paid annual
Payout Ratio
391.7%High
Payback Period
51.1 yr
Last Ex-Dividend
Jun 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.45BCNY363.20M · vs all stocks (USD)
Revenue (TTM)
1.13BCNY167.33M · vs all stocks (USD)
Profit Margin
-2.24%vs Biotechnology peers
Beta
1.03xvs all stocks
52-Week Change
0.47%vs all stocks
Market Capitalization
2.45BCNY363.20M · vs all stocks (USD)
Enterprise Value
1.36BCNY202.07M · vs all stocks (USD)
Price to Sales (TTM)
2.24xvs Biotechnology peers
Price to Book (MRQ)
1.25xvs Biotechnology peers
Enterprise to Revenue
1.21xvs Biotechnology peers
Enterprise to EBITDA
-30.22xvs Biotechnology peers
Gross Margin
20.31%vs Biotechnology peers
Profit Margin
-2.24%vs Biotechnology peers
Operating Margin
-7.16%vs Biotechnology peers
Return on Assets (TTM)
-1.73%vs Biotechnology peers
Return on Equity (TTM)
-1.25%vs Biotechnology peers
Revenue (TTM)
1.13BCNY167.33M · vs all stocks (USD)
Revenue per Share (TTM)
12.90CNYUpdated Aug 20, 2026Quarterly Revenue Growth
19.80%vs Biotechnology peers
Gross Profit (TTM)
214.36MCNY31.84M · vs all stocks (USD)
EBITDA (TTM)
-45.02MCNY-6.69M · vs all stocks (USD)
Net Income (TTM)
-25.24MCNY-3.75M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-10.59%vs Biotechnology peers
Operating Cash Flow (TTM)
-44.73MCNY-6.64M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-132.92MCNY-19.74M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.6000CNYUpdated Aug 20, 2026Trailing Annual Dividend Yield
1.76%vs all stocks
Payout Ratio
391.67%vs Biotechnology peers
Revenue
1.08BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
880.13MCNYFY2025 · Dec 31, 2025Gross Profit
203.57MCNYFY2025 · Dec 31, 2025Operating Income
-41.95MCNY-6.23M · vs all stocks (USD)
Pre-tax Income
-33.67MCNYFY2025 · Dec 31, 2025Income Tax Expense
-10.72MCNYFY2025 · Dec 31, 2025Net Income
-22.95MCNYFY2025 · Dec 31, 2025EBIT
-32.76MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-4.95MCNYFY2025 · Dec 31, 2025Research & Development
67.01MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
23.11MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.27MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.01MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
904.42KCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.2600CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.2600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
88.26MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
88.26MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-22.95MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-31.20MCNYFY2025 · Dec 31, 2025Free Cash Flow
-127.16MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
545.52MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-22.95MCNYFY2025 · Dec 31, 2025Other Non-cash Items
5.78MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
669.66KCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-14.70MCNYFY2025 · Dec 31, 2025Capital Expenditures
-95.96MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.15BCNYFY2025 · Dec 31, 2025Sale of Investments
3.91BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-334.33MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
44.47MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
0.00CNYFY2025 · Dec 31, 2025Common Dividends Paid
-19.98MCNYFY2025 · Dec 31, 2025Other Financing Charges
-25.95MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-1.46MCNYFY2025 · Dec 31, 2025Shares Outstanding
86.67MSharesUpdated Aug 20, 2026Float Shares
40.22MSharesUpdated Aug 20, 2026% Held by Insiders
53.74%vs all stocks
% Held by Institutions
4.08%vs all stocks
Total Cash (MRQ)
1.21BCNY179.29M · vs all stocks (USD)
Total Cash per Share (MRQ)
14.21CNYUpdated Aug 20, 2026Total Debt (MRQ)
78.35MCNY11.64M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0393xvs Biotechnology peers
Current Ratio (MRQ)
6.47xvs Biotechnology peers
Book Value per Share (MRQ)
23.46CNYUpdated Aug 20, 2026Total Assets
2.30BCNY341.96M · vs all stocks (USD)
Total Current Assets
1.87BCNYFY2025 · Dec 31, 2025Total Liabilities
296.56MCNYFY2025 · Dec 31, 2025Total Non-current Assets
433.24MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
11.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
285.21MCNYFY2025 · Dec 31, 2025Cash
542.70MCNYFY2025 · Dec 31, 2025Cash Equivalents
2.82MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
545.52MCNYFY2025 · Dec 31, 2025Other Short-term Investments
803.59MCNYFY2025 · Dec 31, 2025Accounts Receivable
362.85MCNYFY2025 · Dec 31, 2025Inventory
128.47MCNYFY2025 · Dec 31, 2025Accounts Payable
96.43MCNYFY2025 · Dec 31, 2025Short-term Debt
49.05MCNYFY2025 · Dec 31, 2025Other Current Liabilities
7.12MCNYFY2025 · Dec 31, 2025Long-term Debt
4.59MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
4.20MCNYFY2025 · Dec 31, 2025Common Stock (Book)
86.67MCNYFY2025 · Dec 31, 2025Retained Earnings
197.00MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.01BCNY297.91M · vs all stocks (USD)
Treasury Stock
37.76MCNYFY2025 · Dec 31, 202552-Week Low
23.89CNYUpdated Aug 20, 202652-Week High
36.42CNYUpdated Aug 20, 202652-Week Change
0.47%vs all stocks
Beta
1.03xvs all stocks
50-Day MA
26.69CNYUpdated Aug 20, 2026200-Day MA
30.21CNYUpdated Aug 20, 2026Avg 10-Day Volume
1.88MSharesUpdated Aug 20, 2026Avg 30-Day Volume
1.51MSharesUpdated Aug 20, 2026Diluted EPS (TTM)
-0.2900CNYUpdated Aug 20, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 6.32: safe zoneNotable
Altman Z-Score: 6.32
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Lexeo Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aprilbio Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang East-Asia Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Sito Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Tailin Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Avery Dennison Corporation
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Mastercard Incorporated
1 interpretationIndustry-Benchmarked Return on Capital Elevated
Financial Partners Group Co., Ltd.
1 interpretationIndustry-Benchmarked Return on Capital Elevated